Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
6 min read
Precise Therapy for Leukemia – IDH1 Inhibitors
22 September 2023
IDH includes three subtypes -IDH1, IDH2, and IDH3. Depending on the subtype, they can be monomers, homodimers, and polymers.
Drug Insights
4 min read
Decoding Pyridostigmine bromide: A Comprehensive Study of its R&D Trends
22 September 2023
This article summarized the latest R&D progress of Pyridostigmine bromide, the Mechanism of Action for Pyridostigmine bromide, and the drug target R&D trends for Pyridostigmine bromide.
Latest Hotspot
3 min read
Otsuka and Astex declare the European Commission's authorization of INAQOVI® (oral decitabine and cedazuridine) to treat myeloid leukaemia
22 September 2023
Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc. announced EC's approval of INAQOVI® for treating newly diagnosed acute myeloid leukaemia in adults unfit for standard induction chemotherapy.
Drug Insights
4 min read
Deep Scientific Insights on Pramipexole dihydrochloride's R&D Progress
22 September 2023
This article summarized the latest R&D progress of Pramipexole dihydrochloride, the Mechanism of Action for Pramipexole dihydrochloride, and the drug target R&D trends for Pramipexole dihydrochloride.
Advanced Tech.
6 min read
An Indispensable Link in Tumor Treatment: Cell Therapy
22 September 2023
Cell therapy refers to the transplantation or infusion of normal or bioengineered human cells into a patient’s body.
Drug Insights
4 min read
Melphalan Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
22 September 2023
This article summarized the latest R&D progress of Melphalan, the Mechanism of Action for Melphalan, and the drug target R&D trends for Melphalan.
Latest Hotspot
3 min read
Atamyo Therapeutics, known as ATA-200, designed to treat Limb-Girdle Muscular Dystrophy Type 2C/R5, achieves significant progress
22 September 2023
Atamyo Therapeutics made public its submission of a CTA for ATA-200 in European territories.
Drug Insights
4 min read
Unleashing the Power of lemborexant: A Comprehensive Review on R&D Breakthroughs
22 September 2023
This article summarized the latest R&D progress of lemborexant, the Mechanism of Action for lemborexant, and the drug target R&D trends for lemborexant.
Bio Sequence
2 min read
Quickly Locating Your Target Sequence in Patent Claims Containing a Large Number of Antibody Sequences
22 September 2023
In the vast sea of patents, pinpointing a target sequence can be daunting. Utilizing the Patsnap patent database, alongside its Bio Database, simplifies this process.
Drug Insights
4 min read
A Comprehensive Review of Insulin degludec's R&D Innovations and Drug Target Mechanism
22 September 2023
This article summarized the latest R&D progress of Insulin degludec, the Mechanism of Action for Insulin degludec, and the drug target R&D trends for Insulin degludec.
Latest Hotspot
4 min read
BeiGene reports positive regulatory developments in Europe and the U.S., following the recent reacquisition of worldwide rights to TEVIMBRA®
22 September 2023
BeiGene, Ltd. revealed that TEVIMBRA®(tislelizumab) has received approval by the EC to be used as a single therapy for addressing unresectable.
Drug Insights
4 min read
Pharmaceutical Insights: Inosine's R&D Progress and its Mechanism of Action on Drug Target
22 September 2023
This article summarized the latest R&D progress of Inosine, the Mechanism of Action for Inosine, and the drug target R&D trends for Inosine.